Found 11 clinical trials
The Evaluation of the Effect of Performing Guided Lid Surgery
to evaluate the percentage of bone volume regain along with postoperative pain in cases done using the bone lid technique in comparison with those done using the conventional cyst enucleation technique.
- 0 views
- 13 May, 2022
- 1 location
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease
N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir. However, a concern is that CD8 T cells may be excluded from the B cell follicles, where a significant part of the reservoir resides. Webb, …
- 0 views
- 12 May, 2022
- 2 locations
Rituximab and Pegfilgrastim in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Pegfilgrastim may stimulate the immune system in different ways and stop cancer …
- 46 views
- 07 Nov, 2020
- 1 location
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 (IL-2)
This study is meant to assess the use of intralesional IL-2 to modulate the immunological response to suspected melanoma, or melanoma in situ, in an effort to increase lymphocyte infiltration and decrease disease metastasis. Patients that are clinically diagnosed with suspected Melanoma or Melanoma in situ will be assigned to …
- 0 views
- 05 Mar, 2022
- 1 location
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and …
- 0 views
- 05 May, 2022
- 4 locations
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ (SENTINOT_2)
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessary and should be avoided. This includes but is not limited to patients with a preoperative diagnosis …
- 0 views
- 19 Apr, 2022
- 8 locations
Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the patients. Specific
- 128 views
- 26 May, 2022
- 1 location
The PREDICT Registry for DCIS Patients With DCISionRT Testing (PREDICT)
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes that can be queried to determine the utility of the DCISionRT test …
- 191 views
- 27 Feb, 2022
- 64 locations
The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes that can be queried to determine the utility of the DCISionRT test …
- 2 views
- 28 Sep, 2021
- 2 locations
Characterization of Dyschromic Hypertrophic Scar
Currently, there are limited prevention or treatments available for dyschromia in burn hypertrophic scars (HTSs). The limited available techniques involve transferring melanocytes from unaffected areas to the scar to adjust pigment. These techniques involve the creation of a donor site and do not utilize the cells that may already be …
- 0 views
- 08 Mar, 2022
- 1 location
- 1
- 2